In 2021, ivosidenib received approval for IDH1-mutated cholangiocarcinoma [88], and in 2024, vorasidenib, a dual inhibitor of mutated IDH1/2, received FDA approval for glioma [89]. Here, IDH1 is linked to cholangiocarcinoma.